Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy.
Sidsel PedersenRikke B HolmstroemAnnika von HeymannLaerke K TolstrupKasper MadsenMorten Aagaard PetersenCharlotte A HaslundChristina H RuhlmannHenrik SchmidtChristoffer JohansenInge Marie SvaneEva EllebaekPublished in: Acta oncologica (Stockholm, Sweden) (2023)
Adjuvant nivolumab may affect some aspects of QoL, but the influence seems temporary. Patient characteristics, such as civil status, employment status, and comorbidity were associated with HRQoL.